# A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

> **NCT00845910** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 22 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** capecitabine [Xeloda]
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00845910
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** To be confirmed
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845910, "A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00845910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*